Trial Profile
A Study of RG7625 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Petesicatib (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
- 12 Feb 2021 Data from two studies (NCT02295332 [SAD] & NCT02521610 [MAD])) was used for pharmacokinetic analysis, published in the British Journal of Clinical Pharmacology.
- 11 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Apr 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.